

## **HIV and Its Syndemic Partners**

Pamela Talley, MD, MPH Medical Director HIV/STI/VH

24rd Annual HIV Symposium November 5, 2021



- Review Tennessee epidemiologic data
  - HIV
  - Hepatitis C
  - STI
  - Overdose deaths
- Describe End the Syndemic Tennessee





# Current Epidemiology of HIV in Tennessee

### Current overview of HIV, Tennessee 2020


# **19,214** Persons living with HIV (PLWH)

# 651 Persons newly diagnosed with HIV

# **300** Deaths among persons living with HIV




## PLWH identified by gender, Tennessee 2020






## Persons living with HIV by age group, Tennessee, 2016–2020






## Persons living with HIV by race/ethnicity, Tennessee, 2016–2020






# Persons newly diagnosed with HIV, by stage within 12 months of diagnosis, Tennessee, 2016–2020



2016 2017 2018 2019 2020 ■ HIV Stages 0–2 and Stage 3 (AIDS) concurrently ■ HIV Stages 0–2




## Persons newly diagnosed with HIV by age group, Tennessee, 2016–2020






# MSM newly diagnosed with HIV by race/ethnicity, Tennessee 2016–2020

Rate per 100,000 males





## Deaths among persons diagnosed with HIV, Tennessee 2015–2019








## **HIV Continuum of Care**

## HIV continuum of care metrics Tennessee, 2019

- **Diagnosed:** Living with diagnosed HIV in TN at end of 2019
- Linked to Care: Among newly diagnosed in 2019, ≥1 CD4 or viral load result within 30 days after HIV diagnosis
- Engaged in Care: Among those diagnosed with HIV before 2010 and living with diagnosed HIV in TN at end of 2019,
   ≥2 CD4 and/or viral load results ≥3 months apart
- Virally Suppressed: Among those living with diagnosed HIV in TN at end of 2019, ≥1 viral load result in 2018, and ≥1 viral load result in 2019 with the last ≤ 200 copies/mL



## Continuum of care, Tennessee, 2019




Diagnosed Linked to Care, 30 days Engaged in Care Virally Suppressed



\*Variables have different denominators.

## Continuum of care by race/ethnicity, Tennessee, 2019




Non-Hispanic WhiteNon-Hispanic BlackHispanicOtherLinked to Care, 30 daysEngaged in CareVirally Suppressed




\*Other Race includes Asian, Native American/Alaskan Native, and Native Hawaiian/Pacific Islander.

## Continuum of care by age group, Tennessee, 2019






## Continuum of care by region, Tennessee, 2019





### Continuum of care by Ryan White Part B status, Tennessee, 2019




■ Linked to Care, 30 days ■ Engage

Engaged in Care

Non-Ryan White Virally Suppressed



## Continuum of care, Tennessee, 2015–2019





# Perinatal HIV Exposure in TN

TN


## Perinatal HIV Exposure in TN

#### Perinatal HIV exposure among infants born in TN, by year 2015-2019 Potential Exposed, No. Exposed, No. 90 Seroreverters, No. Pediatric HIV, No. 80 70 60 50 40 30 20 10 0 2015 2016 2018 2019 2017 Year Note: 2019 data is provisional.

TN Department of Health

Source: Tennessee Enhanced HIV/AIDS Reporting System (eHARS), July 2021

## **Birthing Parent Characteristics (2015–2019)**





## Hepatitis C in Tennessee



## HCV trends in TN, 2014–2018

# 193% increase in the number of newly reported chronic HCV cases

#### Individuals <45 years of age accounted for

- 52% of new chronic HCV cases
- 81% of acute HCV cases

#### Women accounted for

 48% of acute and 49% of newly reported chronic HCV cases among individuals <45 years of age</li>



## Adult HCV testing recommendations

Testing every adult **at least** once

Testing pregnant persons during every pregnancy

Testing persons who currently inject drugs and share needles, syringes, and other drug preparation equipment regularly



## **HCV vertical transmission**

### HCV monoinfection: 6%

- HCV RNA levels correlate with risk of vertical HCV transmission
- Persons who are HCV antibody (+) and HCV RNA (-) have a negligible risk of transmission


### **Risk factors for vertical transmission**

- Prolonged rupture of membranes (longer than 6 hours)
- Obstetric procedures and intrapartum events that lead to infant exposure to HCV-infected blood (e.g., internal fetal monitoring, vaginal/perineal lacerations)
- Injection-drug use
- HIV coninfection

Benova L, et al. Clin Infect Dis. 2014;59(6):765-773; European Paediatric Hepatitis C Virus Network. J Infect Dis. 2005;192(11):1872-1879; Tosone G, et al. World J Hepatol. 2014;6(8):538-548; Resti M, et al. J Infect Dis. 2002;185(5):567-572.



## Infant HCV testing recommendations





https://www.aappublications.org/news/2021/02/26/hepatitis-screening-pregnancy-022621

## **Convergence of risks in women**

From 2000–2015, rates of HCV increased 148% among women with opioid use disorder

During the same time period the national rate of HCV among women giving birth increased >400%








https://www.cdc.gov/mmwr/volumes/68/wr/mm6839a1.html

## **Rates of perinatal HCV exposures in TN**




# In 2018, there were 1,389 infants perinatally exposed to HCV statewide



https://www.tn.gov/content/dam/tn/health/documents/viral-hepatitis/2018%20Epi%20Profile\_Final.pdf

50.0-109.8

## **Perinatal HCV exposures in Eastern TN**



### In 2018, there were 504 infants perinatally exposed to HCV in Knoxville and the 15 surrounding counties

### Of these 504 exposures <u>only 22 (4%) infants were</u> <u>tested appropriately for HCV</u> and 482 *still* had an unknown HCV status in 2021



of https://www.tn.gov/content/dam/tn/health/documents/viral-hepatitis/2018%20Epi%20Profile\_Final.pdf

## **Educational materials—mothers**

### Hepatitis C and Pregnant Women Brochure

- English
- Spanish
- Arabic

### **Available on TDH Website**

https://www.tn.gov/health/cedep/vira I-hepatitis/hepatitis-c.html



#### HEPATITIS C AND PREGNANT WOMEN

Have you been exposed to hepatitis C? Are you pregnant or planning to have a baby?





Developed by the Tennessee Department of Health

## **Educational Materials—infants**

Infant Hepatitis C Testing Recommendations One-Pager

### To request a PDF copy, email Laura Price

- Laura.Price@tn.gov

resting recommendations for cin	ldren Born to Hepatitis C Virus-Positive Mothers
If Child is:	Order the Following Test(s):
2 Months of Age–18 Months of Age	Hepatitis C Virus RNA
18 Months of Age and Older	Hepatitis C Virus Antibody and, if positive, Hepatitis C Virus RNA
Frequ	ently Asked Questions
y are infants not tested with hepatitis C virus	antibody prior to 18 months of age?
Hepatitis C virus antibody testing before likely reflect maternal hepatitis C virus an	18 months of age is not recommended as a positive result could
likely reflect filaternal fiepatitis C virus al	ubodies
here a risk that a hepatitis C virus-positive mo	ther will vertically transmit hepatitis C virus to her infant during
there a risk that a hepatitis C virus-positive mo egnancy?	
there a risk that a hepatitis C virus-positive mo egnancy? • A mother must be viremic (hepatitis C vir virus to her infant	ther will vertically transmit hepatitis C virus to her infant during



Developed by the Tennessee Department of Health

## **Upcoming HCV training opportunity**

#### From Diagnosis to Treatment: Building an HCV Toolkit





#### Date & Time

12/17/2021 - 8:00 AM - 12:00 PM Central Time

#### Description

Join the TN AETC and **Cody Chastain, MD** for a 3.5 hour clinical training program on diagnosing and treating hepatitis C!

#### Target Audience:

This half-day training program is designed for clinical providers who are new to HCV treatment. It's best suited for **physicians**, **physician assistants**, **nurse practitioners**, **pharmacists**, and **nurses**.

https://www.seaetc.com/event/?ER\_ID=83848



# Sexually Transmitted Infections

#### December 18, 2020

Morbidity and Mortality Weekly Report

#### Update to CDC's Treatment Guidelines for Gonococcal Infection, 2020

Sancta St. Cyr, MD<sup>1</sup>; Lindley Barbee, MD<sup>1,2</sup>; Kimberly A. Workowski, MD<sup>1,3</sup>; Laura H. Bachmann, MD<sup>1</sup>; Cau Pham, PhD<sup>1</sup>; Karen Schlanger, PhD<sup>1</sup>; Elizabeth Torrone, PhD<sup>1</sup>; Hillard Weinstock, MD<sup>1</sup>; Ellen N. Kersh, PhD<sup>1</sup>; Phoebe Thorpe, MD<sup>1</sup>

https://www.cdc.gov/mmwr/volumes/69/wr/mm6950a6.htm?s\_cid=mm6950a6\_w



## **NEW** Gonorrhea Treatment Guidelines



National Network of STD Clinical Prevention Training Centers

for uncomplicated infections

#### Ceftriaxone <u>500</u> mg IM x 1 for persons weighing <150kg\*

\*For persons weighing ≥ 150kg, 1 g of IM ceftriaxone should be administered

<u>IF</u> chlamydia has <u>not</u> been excluded, treat for chlamydia with:

Doxycycline 100 mg PO BID x 7 days

For pregnancy, allergy, or concern for nonadherence, 1g PO azithromycin x 1 can be used

#### No longer recommending dual therapy with azithromycin


Update to CDC's Treatment Guidelines for Gonococcal infection, MMWR 2020



National Network of STD Clinical Prevention Training Centers

#### **NEW Alternative** Gonorrhea Treatment

for uncomplicated infections of the cervix, urethra, and rectum if ceftriaxone is not available:



#### No reliable alternative treatments are available for pharyngeal gonorrhea

Update to CDC's Treatment Guidelines for Gonococcal infection, MMWR 2020



Morbidity and Mortality Weekly Report

July 23, 2021

#### Sexually Transmitted Infections Treatment Guidelines, 2021



#### **NEW Chlamydia** Treatment Guidelines



National Network of STD Clinical Prevention Training Centers

for uncomplicated infections

Doxycycline 100 mg

PO BID x 7 days

For pregnancy, allergy, or concern for non-adherence Azithromycin 1 gram

PO in single dose

OR

Levofloxacin 500 mg orally orally once daily for 7 days

Strong doxycycline preference, especially for rectal infections


Source: CDC STI Treatment Guidelines, 2021

Clinical Infectious Diseases



Doxycycline Versus Azithromycin for the Treatment of Rectal Chlamydia in Men Who Have Sex With Men: A Randomized Controlled Trial

Jalia C. Dombrowski,<sup>12</sup> Michael R. Wierzbicki,<sup>3</sup> Lori M. Newman,<sup>4</sup> Jonathan A. Powell,<sup>3</sup> Ashfey Miller,<sup>5</sup> Dwyn Dithmer,<sup>7</sup> Olusogun O. Soge,<sup>4</sup> and Kenneth H. Mayer<sup>28</sup>






National Network of STD Clinical Prevention Training Centers

- Randomized placebocontrolled trial
- 177 participants enrolled, 135 (76%) met CC population
- 7-day course of doxycycline was significantly more effective than a single dose of azithromycin

#### Source: Dombrowski et al, CID 2021

#### Congenital syphilis trends, U.S. and Tennessee



Source: Patient Reporting Investigation Surveillance Manager (PRISM), 2016–2020. \*2020 national rates not available.



# Drug Overdose Deaths in Tennessee



#### Increase in drug overdoses during COVID-19, Tennessee

Published August 2020

#### **Nonfatal Opioid Overdose**



From March-June of 2020, TN saw a 33% increase in nonfatal opioid overdoses compared to March-June of 2019



Among ages 18-44, nonfatal overdoses increased roughly **40%** 

Tennessee is divided into 13 public health regions





All 13 regions have seen **above average** nonfatal opioid overdose counts during COVID-19, and 11 have seen **remarkably elevated** counts



https://www.tn.gov/health/health-program-areas/pdo/pdo/facts-figures.html

#### Overdose deaths, Tennessee Jan–June 2020



Tennesseans died of a drug overdose between **January - June 2020** 






https://www.tn.gov/health/health-program-areas/pdo/pdo/facts-figures.html

#### All drug overdose deaths

# Age-Adjusted Rates for All Drug Overdose Deaths by Sex and Race in TN by Year for 2015-2019<sup>\*</sup>




\*Analysis by the Office of Informatics and Analytics, TDH (last updated December 10, 2020). Limited to TN residents. Data Source: TN Death Statistical File



## All drug overdose deaths

# Opioids, Benzodiazepines, and Stimulants Present in All Drug Overdoses in TN by Year for 2015-2019<sup>\*</sup>



\*Analysis by the Office of Informatics and Analytics, TDH (last updated November 12, 2020). Limited to TN residents. Data Source: TN Death Statistical File. Categories in this graph are not mutually exclusive.

TN




# End the Syndemic Tennessee



Amber Coyne, MPH End the Syndemic Coordinator <u>amber.coyne@tn.gov</u> <u>endthesyndemic.tn@tn.gov</u>




#### What inspired End the Syndemic Tennessee?



Ending the HIV Epidemic plans that exist or are in development (NASTAD)




#### What inspired End the Syndemic Tennessee?




#### Ending the HIV Epidemic plans that exist or are in development (NASTAD)

Federal assessment showing the most vulnerable counties to a HIV/hepatitis C outbreak due to injection drug use (CDC)






#### Overlapping epidemics that fuel each other are called a SYNDEMIC




# Health conditions in a syndemic are connected by




# Health conditions in a syndemic are connected by

DATA




## Health conditions in a syndemic are connected by DATA


BIOLOGY



### Health conditions in a syndemic are connected by DATA BIOLOGY BEHAVIOR



#### Health conditions in a syndemic are connected by DATA BIOLOGY BEHAVIOR SOCIAL DETERMINANTS OF HEALTH




# An integrated prevention and treatment plan for HIV, sexually transmitted infections, substance use disorder and viral hepatitis in Tennessee






#### **ETS TN**

- Internal workgroup including key staff from relevant communicable disease programs, the Ryan White Part B program, TN Department of Mental Health and Substance Abuse Services and the Opioid Response Coordination Office
- Aligned with existing national and local planning guidance








#### ETS TN (cont.)

#### Established regional planning groups












#### ETS TN (cont.)

#### Established regional planning groups




Local Tri-Chairs State Department Representatives Regional Core Leadership Team



#### ETS TN (cont.)

#### Invite community partners




# More than 335 community partners formally registered

- HIV Planning Groups
- Ryan White Providers
- Funded Prevention Partners
- Drug Prevention Coalitions
- County Health Councils
- Navigators
- Academics
- Students
- Advocacy Groups
- LGBT Organizations
- Housing Organizations
- Public Education
- And More...








Increase combined screening of HIV, sexually transmitted infections, substance use disorder, and viral hepatitis at individual points of care








Increase access to appropriate HIV, sexually transmitted infection, substance use disorder, and viral hepatitis prevention services including harm reduction








Increase engagement in appropriate HIV, sexually transmitted infection, substance use disorder, and viral hepatitis treatment services





# RESPOND

Build resilient communities through coordinated care systems and reducing social and structural barriers to health



### **Public website**



#### Website Features


- End the Syndemic Tennessee Overview
- Project Goals
- Calendar of Events
- Access Meeting Notes
- Survey for Anonymous Feedback
- Registration for the Planning Process
- Syndemic-related Data
- Syndemic-related Programs and Resources





# **ETS TN Language Guidance Document**





Contains preferred terminology related to HIV, sexually transmitted infections, substance use disorder, viral hepatitis, and the communities that have been disproportionately impacted by the syndemic





## Accomplishments

- ETS funded pilot projects statewide
- Regional Overdose Prevention Specialists begin doing PrEP education during naloxone distribution
- New condom distribution partners statewide including an SSP, a sex worker-led organization and the Regional Overdose Prevention Specialists
- One organization adds U=U page to their website
- HIV and HCV testing offered at a rural county fair
- Two new International Overdose Awareness Day Events



Working outside silos to End the Syndemic in Tennessee





#### Email us at Endthesyndemic.tn@tn.gov





#### Acknowledgments

**TDH HIV** Meredith Brantley Samantha Mathieson Jack Marr Robb Garman

**TDH Ryan White Part B Program** 

Josh Rosenfeld Laurie Mauer

**TDH Viral Hepatitis** 

Lindsey Sizemore

**TDH Office of Informatics & Analytics** 

Sanura Latham

#### TDH End the Syndemic

Amber Coyne

